Last update 13 Sep 2025

N-(2-pyrimidyl)butanamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
C11
Target
Bacterial quorum sensing protein
Action
inhibitors
Mechanism
Bacterial quorum sensing protein inhibitors, Bacterial biofilms inhibitors
Therapeutic Areas
Infectious Diseases
Active Indication-
Inactive Indication
Pseudomonas aeruginosa infection
Originator Organization
Université Fédérale Toulouse Midi-PyrénéesUniversité Fédérale Toulouse Midi-PyrénéesUniversité Toulouse III - Paul SabatierUniversité Toulouse III - Paul Sabatier
Active Organization-
Inactive Organization
Université Fédérale Toulouse Midi-PyrénéesUniversité Fédérale Toulouse Midi-PyrénéesUniversité Toulouse III - Paul SabatierUniversité Toulouse III - Paul Sabatier
License Organization-
Drug Highest PhasePendingPreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with N-(2-pyrimidyl)butanamide
Login to view more data
100 Translational Medicine associated with N-(2-pyrimidyl)butanamide
Login to view more data
100 Patents (Medical) associated with N-(2-pyrimidyl)butanamide
Login to view more data
7
Literatures (Medical) associated with N-(2-pyrimidyl)butanamide
01 Mar 2016Antimicrobial agents and chemotherapyQ2 · MEDICINE
Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor
Q2 · MEDICINE
01 Aug 2013International journal of molecular medicineQ3 · MEDICINE
Selective inhibition of PCAF suppresses microglial-mediated β-amyloid neurotoxicity
Q3 · MEDICINE
01 Nov 2011Pharmacological reports : PRQ4 · MEDICINE
Oleanolic acid derivative methyl 3,11-dioxoolean-12-en-28-olate targets multidrug resistance related to ABCB1
Q4 · MEDICINE
100 Deals associated with N-(2-pyrimidyl)butanamide
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Pseudomonas aeruginosa infectionPreclinical
France
Université Toulouse III - Paul SabatierUniversité Toulouse III - Paul Sabatier
19 Dec 2015
Pseudomonas aeruginosa infectionPreclinical
France
Université Fédérale Toulouse Midi-PyrénéesUniversité Fédérale Toulouse Midi-Pyrénées
19 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free